

NCCN Basal Cell and Squamous Cell Skin Cancers V.1.2012 — Panel Meeting — August 1, 2011

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p><b><u>Basal Cell Skin Cancer</u></b> <b><u>BCC-B</u></b></p> <p><b>Internal request:</b> Suggestion was made to add methyl aminolevulinate (MAL) as an example of photodynamic therapy.</p>	Based upon available data and panel discussion, the consensus was to add methyl aminolevulinate (MAL) as an example of photodynamic therapy that can be used in patients with low-risk, superficial basal cell skin cancer where surgery or radiation is contraindicated or impractical.	Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. <i>Int J Dermatol</i> 2009;48:1236-1245.	18	0	0
<p><b><u>Squamous Cell Skin Cancer</u></b> <b><u>SCC-6</u></b></p> <p><b>Internal request:</b> For footnote “s”, consider including epidermal growth factor receptor (EGFR) inhibitors such as cetuximab as an option for incurable disease.</p>	Based upon limited case series reports and phase II data, the panel consensus was to revise footnote “s” regarding the treatment of patients with regional recurrence or distant metastases as follows: “Cisplatin, either as a single agent or combined with 5FU, and <i>EGFR inhibitors</i> (eg, <i>cetuximab</i> ) have <i>each</i> occasionally produced useful responses, but data supporting efficacy are limited.”	<ol style="list-style-type: none"> <li>1. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. <i>J Clin Onc</i> 2011;29:3419-3426.</li> <li>2. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. <i>The Oncologist</i> 2010;15:1320-1328. Epub 2010 Dec 8.</li> </ol>	18	0	0
<p><b><u>Squamous Cell Skin Cancer</u></b> <b><u>SCC-B</u></b></p> <p><b>Internal request:</b> Suggestion was made to add methyl aminolevulinate (MAL) as an example of photodynamic therapy.</p>	Based upon available data and panel discussion, the consensus was to add methyl aminolevulinate (MAL) as an example of photodynamic therapy that can be used in patients with low-risk, squamous cell carcinoma in situ where surgery or radiation is contraindicated or impractical.	Fai D, Arpaia N, Romano I, Vestita M, et al. Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients. <i>G Ital Dermatol Venereol</i> 2009;144:281-285.	18	0	0
<p><b><u>Squamous Cell Skin Cancer</u></b> <b><u>SCC-D 2 of 3</u></b></p> <p><b>Internal request:</b> Consider adding diclofenac for the treatment of precancers.</p>	Based upon available data, the panel consensus was to add diclofenac as another therapeutic option to consider for the treatment of actinic keratoses.	<ol style="list-style-type: none"> <li>1. Ulrich C, Johannsen Antje, Ulrich M, et al. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. <i>Eur J Dermatol</i> 2010;20:482-488.</li> <li>2. Akarsu S, Aktan S, Atahan A. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. <i>Clinical Dermatology</i> 2011;36:479-484.</li> </ol>	18	0	0